Global Orthobiologics Market Trends, Forecast Report 2025-2037
Orthobiologics Market size is predicted to rise from USD 8.46 billion to USD 17.04 billion, witnessing a CAGR of over 5.7% during the forecast timeline, from 2025 through 2037. In the year 2025, the industry size of orthobiologics is evaluated at USD 8.84 billion.
The market growth primarily be ascribed to rising cases of bone diseases across the globe. Based on the report provided by the National Library of Medicine (NLM), it was observed that around 1.5 million people suffer from fractures owing to some sort of bone disease every year.
Growing prevalence of low immunity and calcium deficiency owing to changing lifestyles and skyrocketing spending on medical technology are projected to influence the market revenue. As of 2019, the total revenue generated by medical technology was anticipated to be nearly USD 450 billion while the R&D spending on this technology was estimated to be around USD 30 billion in the same year. Orthobiologics is an injectable therapy that utilizes biological substances to heal musculoskeletal injuries rapidly. The substances used in the therapy are made from the materials naturally produced by the body.
Orthobiologics Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Number of Bone Fractures to Boost the Market Growth
- For instance, the estimated number of bone fractures received is approximately 1000 fractures per 100,000 people every year.
- Increasing Sales of Orthopedic Devices
- As of 2022, the orthopedic devices segment was valued at around USD 40 billion.
- A wide array of technologies is included in orthobiologics to improve the functionality of the broken bone. Components such as, scaffolds to reinforce tissue, cell therapies, and bone grafting materials are used in the therapy. Orthobiologics is associated with bone injuries, for instance, osteoporosis, osteonecrosis, bone infection, and density.
- Higher Prevalence of Orthopedic Injuries
- The prevalence of orthopedic injuries can be observed by the fact that more than 6 million orthopedic surgeries are performed every year solely in the USA.
- Rising Cases of Osteoporosis Across the Globe
- It is observed that 1 in 2 women and 1 in 5 men aged 50 or over suffer from osteoporosis globally. Furthermore, in 2017-18, more than 18% of women were predicted to be living with osteoporosis.
- Significant growth in the Healthcare Expenditure
- World Bank published statistics showing that in 2019, the healthcare expenditure reached 1,121.9 U.S. dollars per Capita.
Challenges
- Higher Cost Associated with the Treatment
- Lack of Skilled Medical Professionals and Requisite Technology
- Presence of the Alternatives in the Market
Orthobiologics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.7% |
|
Base Year Market Size (2024) |
USD 8.46 billion |
|
Forecast Year Market Size (2037) |
USD 17.04 billion |
|
Regional Scope |
|
Orthobiologics Segmentation
End-user (Clinics, Hospitals)
The hospitals segment in the orthobiologics market is projected to witness noteworthy growth over the forecast period. The growth of the segment can be accounted to the rising patient pool in hospitals worldwide. For instance, in 2019, approximately 7% of the US population was noticed to be hospitalized.
Our in-depth analysis of the global orthobiologics market includes the following segmen
|
By Solutions |
|
|
By Application |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportOrthobiologics Industry - Regional Synopsis
The North America region is expected to hold majority market share by the end of 2037. The growth of the market can be ascribed to rising geriatric population with severe bone diseases and the ongoing development in the healthcare expenditure of the region. As per the data published by the World Bank, it was noticed that the geriatric population in the United States reached 56,545,938 in 2021.
Companies Dominating the Orthobiologics Landscape
- Medtronic plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Wright Medical Group N.V.
- Zimmer Biomet Holdings, Inc.
- Arthrex, Inc.
- Medical Device Business Services, Inc.
- Johnson & Johnson & Services, Inc.
- RTI Surgical, Inc.
- MTG Learning Media Pvt. Ltd.
- Bioventus LLC
- Stryker Corporation
In the News
- Johnson & Johnson & Services, Inc.’s Janssen Pharmaceutical Company to announce its acquisition of U.S. FDA approval for IMBRUVIGA (ibrutinib). IMBRUVIGA is a BTKi treatment for pediatric patients with chronic graft-versus-host disease (cGVHD) after the failure of systemic therapy.
- Zimmer Biomet Holdings, Inc. announces its three-year agreement with Hospital for special surgery (HSS). The agreement is established to make HSS/Zimmer Biomet (ZB) Innovation Center for Artificial Intelligence (AI).
Author Credits: Radhika Pawar
- Report ID: 773
- Published Date: Jan 17, 2025
- Report Format: PDF, PPT
